Protalix Biotherapeutics KOL Breakfast: Protalix Presents following Elfabrio®’s Approvals for Fabry Disease in the US and the EU
About The Event
Join us in-person for a KOL Breakfast with Protalix Biotherapeutics, discussing the recent FDA approval of Elfabrio® (pegunigalsidase alfa-iwxj) in the United States for the treatment of adult patients with Fabry disease.
- Ankit Mehta, MD, FASN (Baylor University Medical Center) will discuss the opportunity for Elfabrio® to address the unmet needs in Fabry disease.
- Giacomo Chiesi, Head of Chiesi Global Rare Diseases, Protalix’s commercial partner, will discuss Chiesi’s commercial capabilities.
- Protalix leadership will provide insight into the Company’s strategy and future plans.
A live question and answer session will follow the formal presentations.